Evidence map›Paper›PMID 40028358›Full record

ArticleACS central science2025

Bayesian Optimization over Multiple Experimental Fidelities Accelerates Automated Discovery of Drug Molecules.

Matthew A McDonald, Brent A Koscher, Richard B Canty, Jason Zhang, Angelina Ning, Klavs F Jensen

Abstract read
In one paragraph

Article in ACS central science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Applying Deep-Learning-DrivenJournal of medicinal chemistry · 2026
    Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Matthew A McDonaldMassachusetts Institute of Technology, Department of Chemical Engineering, 77 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States.ORCID https://orcid.org/0000-0002-9444-3253
Brent A KoscherMassachusetts Institute of Technology, Department of Chemical Engineering, 77 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States.
Richard B CantyMassachusetts Institute of Technology, Department of Chemical Engineering, 77 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States.ORCID https://orcid.org/0000-0002-2347-2743
Jason ZhangMassachusetts Institute of Technology, Department of Chemical Engineering, 77 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States.ORCID https://orcid.org/0009-0000-5973-9588
Angelina NingMassachusetts Institute of Technology, Department of Chemical Engineering, 77 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States.
Klavs F JensenMassachusetts Institute of Technology, Department of Chemical Engineering, 77 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States.ORCID https://orcid.org/0000-0001-7192-580X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Different experiments of differing fidelities are commonly used in the search for new drug molecules. In classic experimental funnels, libraries of molecules undergo sequential rounds of virtual, coarse, and refined experimental screenings, with each level balanced between the cost of experiments and the number of molecules screened. Bayesian optimization offers an alternative approach, using iterative experiments to locate optimal molecules with fewer experiments than large-scale screening, but without the ability to weigh the costs and benefits of different types of experiments. In this work, we combine the multifidelity approach of the experimental funnel with Bayesian optimization to search for drug molecules iteratively, taking full advantage of different types of experiments, their costs, and the quality of the data they produce. We first demonstrate the utility of the multifidelity Bayesian optimization (MF-BO) approach on a series of drug targets with data reported in ChEMBL, emphasizing what properties of the chemical search space result in substantial acceleration with MF-BO. Then we integrate the MF-BO experiment selection algorithm into an autonomous molecular discovery platform to illustrate the prospective search for new histone deacetylase inhibitors using docking scores, single-point percent inhibitions, and dose-response IC

Identifiers

PMID40028358
PMCPMC11869128

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.